{"DataElement":{"publicId":"8064569","version":"1","preferredName":"ALK Tyrosine Kinase Receptor Variation Positive Finding Neoplasm Amino Acid Sequence Date","preferredDefinition":"The date of the ALK tumor sequencing analysis was performed.","longName":"ALK_TUMOR_SEQ_ANALY_DT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5790457","version":"1","preferredName":"ALK Tyrosine Kinase Receptor Variation Positive Finding  Neoplasm Amino Acid Sequence Change","preferredDefinition":"ALK tyrosine kinase receptor (1620 aa, ~176 kDa) is encoded by the human ALK gene. This protein is involved in ligand binding, tyrosine phosphorylation and signal transduction._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism._An alteration or difference from a norm or standard._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._The arrangement of amino acids in a protein. Proteins can be made from 20 different kinds of amino acids, and the structure and function of each type of protein are determined by the kinds of amino acids used to make it and how they are arranged._The act of alteration or modification; changed or altered in form or character.","longName":"5790454v1.0:5790455v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"5790454","version":"1","preferredName":"ALK Tyrosine Kinase Receptor Positive Finding Variation Neoplasm","preferredDefinition":"ALK tyrosine kinase receptor (1620 aa, ~176 kDa) is encoded by the human ALK gene. This protein is involved in ligand binding, tyrosine phosphorylation and signal transduction.:A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.:An alteration or difference from a norm or standard.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C27032:C38758:C25713:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ALK Tyrosine Kinase Receptor","conceptCode":"C27032","definition":"ALK tyrosine kinase receptor (1620 aa, ~176 kDa) is encoded by the human ALK gene. This protein is involved in ligand binding, tyrosine phosphorylation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Variation","conceptCode":"C25713","definition":"An alteration or difference from a norm or standard.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E280779-FEC3-1098-E053-F662850A5F55","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5790455","version":"1","preferredName":"Amino Acid Sequence Change","preferredDefinition":"The arrangement of amino acids in a protein. Proteins can be made from 20 different kinds of amino acids, and the structure and function of each type of protein are determined by the kinds of amino acids used to make it and how they are arranged.:The act of alteration or modification; changed or altered in form or character.","longName":"C13187:C25446","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amino Acid Sequence","conceptCode":"C13187","definition":"The sequence of amino acids along a polypeptide chain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Change","conceptCode":"C25446","definition":"The act of alteration or modification; changed or altered in form or character.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E280779-FED1-1098-E053-F662850A5F55","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E280779-FEE2-1098-E053-F662850A5F55","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"KUMMEROA","dateModified":"2022-02-02","changeDescription":"2022-2-2 ak Released. Workflow and Registration Status Changed per Brenda Duggan; 05.16.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018550","version":"1","preferredName":"Date","preferredDefinition":"The date on which an observation was made or an event occurred.","longName":"DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"MM/DD/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"B54EF112-5457-674A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-28","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-28","modifiedBy":"ZHWENDY","dateModified":"2023-12-12","changeDescription":"8/3/17 tt added Diagnosis CSI. 6/20/17 jk transferred to NCI Standards per confirmation by Brian Campbell as part of Round 5 finalization task, added reg status.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Date of ALK tumor sequencing","type":"Preferred Question Text","description":"Date of ALK tumor sequencing analysis:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D92A0182-03DF-4DAC-E053-4EBD850A9696","latestVersionIndicator":"Yes","beginDate":"2022-03-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-01","modifiedBy":"CLOHNES","dateModified":"2022-09-07","changeDescription":"Curated for ANBL1531 bsm.","administrativeNotes":"9/7/22 Released CDE per AK for COG cjl;","unresolvedIssues":null,"deletedIndicator":"No"}}